Can we prevent breast cancer? The promising new clinical trial with a vaccine.

A new clinical trial at the Cleveland Clinic may be preventing triple-negative breast cancer from recurring. And it could also help those with the BRCA-1, BRCA-2 genes. Patient Chase Johnson and Anixa Biosciences CEO, Dr. Amit Kumar, explain. 00:02:17 — Chase’s treatment path (chemo, surgery, radiation, oral chemo) and why she pursued added protection. 00:03:37 — Trial logistics: waitlist, eligibility timing, travel to Cleveland, scans, and enrollment. 00:04:51 — What the vaccine shots were like (3 injections, spaced 2 weeks apart). Study: https://consultqd.clevelandclinic.org... 00:05:31 — Side effects and why an immune response is considered expected. 00:06:34 — Recurrence timing stats and the significance of the 5-year milestone. 00:07:33 — Dr. Kumar explains the vaccine concept and alpha-lactalbumin target. 00:10:10 — Trial status: phase one complete; phase two planning with more sites nationwide. 00:11:22 — Potential rollout path: treatment, recurrence prevention, then prophylactic use. 00:13:33 — Pregnancy/breastfeeding considerations: likely impacts milk production, not fertility. 00:14:34 — Chase’s post-vaccine peace of mind; immunotherapy as the future. 00:15:13 — Chase’s dog helped detect the lump; self-advocacy when dismissed as “too young.” 00:19:40 — Why TNBC is hard to treat (no ER/PR/HER2 targets) and why it’s aggressive. 00:20:44 — How to track phase two locations; importance of clinical trials and prevention vision. 00:23:24 — Other cancer vaccine research (e.g., ovarian) and closing takeaways on vigilance.